Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02447718 | Vaccinating Children After Chemotherapy | completed | Phase 4 | 156 | Canadian Immunization Research NetworkNETWORK | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05429515 | Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 0 | Jun 23, 2022 | clinicaltrials |
| NCT05183139 |
| A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma(US MM-7) |
| withdrawn |
| Phase 4 |
| 0 |
| TakedaINDUSTRY |
| 0 |
| May 3, 2022 |
| clinicaltrials |
| NCT04349306 | Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia(RAISE) | completed | Phase 4 | 50 | SanofiINDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05340985 | Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis | unknown | Phase 4 | 54 | Tehran University of Medical SciencesOTHER | 0 | Apr 22, 2022 | clinicaltrials |
| NCT05191225 | Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study | unknown | Phase 4 | 48 | Laida Cuevas PalomaresNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT01358201 | PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years | unknown | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT01366898 | Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) | unknown | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05137860 | Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD | unknown | Phase 4 | 56 | Hospital General de MexicoOTHER_GOV | 1 | Jan 18, 2022 | clinicaltrials |
| NCT02323659 | Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas | terminated | Phase 4 | 100 | Polish Lymphoma Research GroupNETWORK | 1 | Jan 13, 2022 | clinicaltrials |
| NCT05133310 | Effect of Simvastatin on Sepsis and Febrile Neutropenia in Patients With Acute Lymphoblastic Leukemia | unknown | Phase 4 | 108 | Hospital General de MexicoOTHER_GOV | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05176119 | Nalbuphine Versus Ketamine for Prevention of Emergence Agitation After Sevoflurane in Children Undergoing Tonsillectomy | completed | Phase 4 | 90 | Ain Shams UniversityOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT04989140 | Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide | unknown | Phase 4 | 60 | Peking Union Medical College HospitalOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT04999878 | A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.(RUE-DDGP) | unknown | Phase 4 | 30 | Zhengzhou UniversityOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT00622505 | Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants(Z-MARK) | completed | Phase 4 | 121 | Novartis PharmaceuticalsINDUSTRY | 1 | May 26, 2021 | clinicaltrials |
| NCT04842318 | Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study | unknown | Phase 4 | 789 | Ruijin HospitalOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT01990534 | A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 4 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 7 | Apr 9, 2021 | clinicaltrials |
| NCT03176849 | A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT | completed | Phase 4 | 49 | Phoenix Children's HospitalOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT04612582 | Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis | unknown | Phase 4 | 70 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04490590 | A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma | unknown | Phase 4 | 30 | Mingzhi ZhangOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT04040491 | PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma | unknown | Phase 4 | 100 | Mingzhi ZhangOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT00853008 | Treatment of High Risk Adult Acute Lymphoblastic Leukemia(LAL-AR/2003) | completed | Phase 4 | 100 | PETHEMA FoundationOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT01087008 | Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse(AZABACHE) | completed | Phase 4 | 103 | PETHEMA FoundationOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT01731886 | Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma | completed | Phase 4 | 60 | Columbia UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02577783 | PDD vs PAD to Treat Initially Diagnosed MM | unknown | Phase 4 | 64 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02773550 | Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma(Velcadito) | terminated | Phase 4 | 24 | Basque Health ServiceOTHER_GOV | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02958969 | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma | completed | Phase 4 | 50 | Gregory PiazzaOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03908138 | RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | unknown | Phase 4 | 120 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 29, 2019 | clinicaltrials |
| NCT01007448 | Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 4 | 59 | Bausch Health Americas, Inc.INDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04152577 | R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL | unknown | Phase 4 | 200 | Shandong Provincial HospitalOTHER_GOV | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04134247 | Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL | unknown | Phase 4 | 120 | Shandong Provincial HospitalOTHER_GOV | 1 | Oct 22, 2019 | clinicaltrials |
| NCT00003398 | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 4 | 45 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT04083066 | Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 4 | 20 | Mingzhi ZhangOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT04083079 | Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma | unknown | Phase 4 | 250 | Ruijin HospitalOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT04038411 | PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma | unknown | Phase 4 | 50 | Mingzhi ZhangOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT03376958 | Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | completed | Phase 4 | 32 | Zhengzhou UniversityOTHER | 1 | Jul 25, 2019 | clinicaltrials |
| NCT03369847 | Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge | completed | Phase 4 | 43 | New York City Health and Hospitals CorporationOTHER | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01180049 | Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | completed | Phase 4 | 101 | PfizerINDUSTRY | 11 | May 20, 2019 | clinicaltrials |
| NCT03920813 | Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy | unknown | Phase 4 | 500 | Shandong UniversityOTHER | 0 | Apr 23, 2019 | clinicaltrials |
| NCT02670564 | ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) | unknown | Phase 4 | 1,000 | Swiss Pediatric Oncology GroupOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02526823 | Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma | unknown | Phase 4 | 360 | Shandong Provincial HospitalOTHER_GOV | 1 | Apr 2, 2019 | clinicaltrials |
| NCT01283386 | A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status | terminated | Phase 4 | 26 | Hoffmann-La RocheINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT02095951 | Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection | completed | Phase 4 | 30 | Children's Hospital of MichiganOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT02933333 | G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor | unknown | Phase 4 | 405 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03707847 | Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL | unknown | Phase 4 | 20 | Mingzhi ZhangOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT03558412 | A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma | unknown | Phase 4 | 40 | Mingzhi ZhangOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03579082 | A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma | unknown | Phase 4 | 60 | Mingzhi ZhangOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03226119 | MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study | completed | Phase 4 | 150 | MP Biomedicals, LLCINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT00221039 | Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A | completed | Phase 4 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT03631862 | Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | unknown | Phase 4 | 100 | Zhengzhou UniversityOTHER | 1 | Aug 15, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Jun 24, 2022source: clinicaltrials